Search results for "delay"

showing 10 items of 814 documents

Deep Neural Network Frontend for Continuous EMG-Based Speech Recognition

2016

030507 speech-language pathology & audiology03 medical and health sciencesArtificial neural networkTime delay neural networkComputer scienceSpeech recognition0206 medical engineering02 engineering and technology0305 other medical science020601 biomedical engineeringInterspeech 2016
researchProduct

Coronavirus disease 2019, Kawasaki disease, and multisystem inflammatory syndrome in children

2020

2019-20 coronavirus outbreakDelayed DiagnosisCoronavirus disease 2019 (COVID-19)Pneumonia ViralMucocutaneous Lymph Node Syndromemedicine.disease_causeDelayed diagnosisArticleBetacoronavirusPandemicmedicineHumansPediatrics Perinatology and Child HealthChildLetter to the EditorPandemicsCoronavirusbiologybusiness.industrySARS-CoV-2COVID-19biology.organism_classificationmedicine.diseaseVirologyMucocutaneous Lymph Node SyndromeCoronavirusPediatrics Perinatology and Child HealthKawasaki diseasebusinessCoronavirus InfectionsBetacoronavirusThe Journal of Pediatrics
researchProduct

PHEA-PLA biocompatible nanoparticles by technique of solvent evaporation from multiple emulsions

2015

Nanocarriers of amphiphilic polymeric materials represent versatile delivery systems for poorly water soluble drugs. In this work the technique of solvent evaporation from multiple emulsions was applied to produce nanovectors based on new amphiphilic copolymer, the α,β-poly(N-2-hydroxyethyl)-DL-aspartamide-polylactic acid (PHEA-PLA), purposely synthesized to be used in the controlled release of active molecules poorly soluble in water. To this aim an amphiphilic derivative of PHEA, a hydrophilic polymer, was synthesized by derivatization of the polymeric backbone with hydrophobic grafts of polylactic acid (PLA). The achieved copolymer was thus used to produce nanoparticles loaded with α toc…

3003Biocompatible polymerPolymersChemistry PharmaceuticalDrug CompoundingPolyestersalpha-TocopherolPharmaceutical Sciencechemistry.chemical_compoundDrug Delivery SystemsNanoparticlePolylactic acidAmphiphileOrganic chemistryLactic AcidSolubilityDrug CarriersUltrasonic energyPHEA-PLAEmulsionAmphiphilic polymerControlled releaseSolventDrug LiberationSolubilitychemistryChemical engineeringDelayed-Action PreparationsDrug deliveryDrug deliverySolventsNanoparticlesEmulsionsNanocarriersPeptidesDrug carrierHydrophobic and Hydrophilic Interactions
researchProduct

Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.

2017

Abstract In this paper, we describe the preparation of polymeric nanoparticles (NPs) loaded with sorafenib for the treatment of hepatocellular carcinoma (HCC). A synthetic brush copolymer, named PHEA-BIB-ButMA (PBB), was synthesized by Atom Trasnfer Radical Polymerization (ATRP) starting from the α-poly( N -2-hydroxyethyl)- d , l -aspartamide (PHEA) and poly butyl methacrylate (ButMA). Empty and sorafenib loaded PBB NPs were, then, produced by using a dialysis method and showed spherical morphology, colloidal size, negative ζ potential and the ability to allow a sustained sorafenib release in physiological environment. Sorafenib loaded PBB NPs were tested in vitro on HCC cells in order to e…

3003MaleHepatocellular carcinomamedicine.medical_treatmentPharmaceutical Science02 engineering and technologyATRPPharmacology01 natural sciencesDrug Delivery SystemsCopolymerChemistryATRP; Hepatocellular carcinoma; Sorafenib; Tumor targeting; α-Poly(N-2-hydroxyethyl)-DL-aspartamide; 3003Liver NeoplasmsSorafenib021001 nanoscience & nanotechnologyDrug delivery0210 nano-technologymedicine.drugSorafenibNiacinamideCarcinoma HepatocellularCell SurvivalRadical polymerizationIntraperitoneal injectionL-aspartamideMice NudeAntineoplastic AgentsEnhanced permeability and retention effect010402 general chemistryPolymethacrylic AcidsIn vivoCell Line TumormedicineAnimalsHumansneoplasmsProtein Kinase InhibitorsPhenylurea Compoundstechnology industry and agriculturedigestive system diseasesIn vitro0104 chemical sciencesDrug LiberationTumor targetingDelayed-Action PreparationsBiophysicsα-Poly(N-2-hydroxyethyl)-DNanoparticlesα-Poly(N-2-hydroxyethyl)-DL-aspartamidePeptidesJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Widening use of dexamethasone implant for the treatment of macular edema

2017

Vincenza Bonfiglio, Michele Reibaldi, Matteo Fallico, Andrea Russo, Alessandra Pizzo, Stefano Fichera, Carlo Rapisarda, Iacopo Macchi, Teresio Avitabile, Antonio Longo Department of Ophthalmology, University of Catania, Catania, Italy Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of effica…

3003intravitrealgenetic structuresimplantmedicine.medical_treatmentPharmaceutical ScienceVitrectomyReviewDrug Implantcorticosteroids0302 clinical medicineGlucocorticoidCentral retinal vein occlusionDrug DiscoveryDelayed-Action PreparationCorticosteroidRandomized Controlled Trials as TopicDrug ImplantsCorticosteroids; Dexamethasone; Implant; Intravitreal; Macular edema; Pharmacology; 3003; Drug Discovery3003 Pharmaceutical ScienceDiabetic retinopathyIntravitreal InjectionsUveitismedicine.drugHumanmedicine.medical_specialtydexamethasone03 medical and health sciencesOphthalmologymedicineHumansMacular edemaGlucocorticoidsDexamethasonePharmacologyMacular edemaDiabetic Retinopathybusiness.industryIntravitreal InjectionDrug Discovery3003 Pharmaceutical Sciencelcsh:RM1-950Macular degenerationmedicine.diseaseeye diseasesSurgerylcsh:Therapeutics. PharmacologyDelayed-Action Preparations030221 ophthalmology & optometryBranch retinal vein occlusionsense organsbusiness030217 neurology & neurosurgeryDrug Design, Development and Therapy
researchProduct

Non-existence of unfair delay in the exercise of claim actio for amounts unduly collected. Comment on Spanish STS no. 243/2019, of April (RJ 2019, 15…

2020

El Tribunal Supremo considera que el mero retraso en el ejercicio de una acción de reclamación de cantidad no puede ser considerado por si sólo constitutivo de retraso desleal. Además, es necesario que previamente al ejercicio del derecho existan hechos, actos o conductas que provoquen en el obligado la confianza de que el derecho en su contra no se ejercitará. The Supreme Court considers that the mere delay in the exercise of an action of claim of quantity cannot be considered to constitute unfair delay. In addition, it is necessary that prior to the exercise of the right there are facts, acts or conducts that cause int the obliged the confidence that the right against him will not be exer…

:CIENCIAS JURÍDICAS [UNESCO]VerwirkungUNESCO::CIENCIAS JURÍDICASplazo de prescripciónaction of claim of quantityterm of prescriptionhumanitieshealth care economics and organizationsacción de reclamación de cantidadretraso deslealunfair delay
researchProduct

Resistance Training Acutely Impairs Agility and Spike-Specific Performance Measures in Collegiate Female Volleyball Players Returning from the Off-Se…

2020

This study examined the acute effects of resistance training (RT) on volleyball-specific performance. Sixteen female volleyball players undertook their initial, pre-season RT bout. Countermovement jump (CMJ), delayed onset of muscle soreness (DOMS), and sport-specific performances (i.e., run-up jump, agility, and spiking speed and accuracy) were measured before, 24 (T24), and 48 (T48) hours after RT. A significant increase in DOMS was observed at T24 and T48 (~207.6% &plusmn

Acute effectsStrength trainingHealth Toxicology and Mutagenesislcsh:MedicinelihaksetAthletic PerformanceMuscle damagechange-of-directionArticle03 medical and health sciencesmuscle damage0302 clinical medicinestrength trainingHumansMedicineMuscle Strengthmuscle sorenessbiologyAthletesbusiness.industrylcsh:RPublic Health Environmental and Occupational HealthDelayed onsetResistance trainingResistance TrainingMyalgia030229 sport sciencesbiology.organism_classificationVolleyballjumpAnesthesiaJumpCountermovement jumpFemalehyppääminenSeasonsvoimaharjoitteluvammatbusinesshuman activities030217 neurology & neurosurgeryInternational Journal of Environmental Research and Public Health
researchProduct

Effect of the basidiomycete Poria cocos on experimental dermatitis and other inflammatory conditions.

1997

The hydroalcoholic extract from P. cocos was examined for oral and topical anti-inflammatory activities. It proved to be active against carrageenan, arachidonic acid, tetradecanoyl phorbol acetate (TPA) acute edemas, TPA chronic inflammation and oxazolone delayed hypersensitivity in mice. Two lanostane-type triterpenes were isolated and identified by spectroscopic methods as dehydrotumulosic and pachymic acids. Their ID50 on acute TPA edema was 4.7 x 10(-3) and 6.8 x 10(-4) mumol/ear, respectively.

Administration TopicalAnti-Inflammatory AgentsAdministration OralDermatitisPharmacognosyPharmacologyCarrageenanOxazolonechemistry.chemical_compoundMiceEdemaDrug DiscoverymedicineAnimalsInflammationArachidonic Acidintegumentary systemPlant ExtractsBasidiomycotaGeneral ChemistryGeneral MedicineTriterpenesCarrageenanchemistryDelayed hypersensitivityTetradecanoylphorbol AcetateImmunologyPhorbolTetradecanoylphorbol AcetateArachidonic acidFemalemedicine.symptomChemicalpharmaceutical bulletin
researchProduct

Does Preoperative Treatment with a Gonadotropin-Releasing Hormone Agonist Improve the Outcome of Endometrial Resection?

1998

Abstract Study Objective. To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment. Design. Multicenter, randomized, controlled trial (Canadian Task Force classification I). Setting. Tertiary care academic department. Patients. Sixty-three premenopausal women with established menorrhagia. Intervention. Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle. Measurements and Main Results. Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determi…

AdultAgonistmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classlaw.inventionEndometriumRandomized controlled triallawGonadotropin-releasing hormone agonistPreoperative CareFollicular phaseElectrocoagulationmedicineHumansProspective StudiesMenorrhagiabusiness.industryGoserelinObstetrics and GynecologyEndoscopyMiddle AgedSurgeryExact testTreatment OutcomeDelayed-Action PreparationsUterine NeoplasmsGoserelinFemaleAmenorrheamedicine.symptombusinessAdenomyomamedicine.drugHormone
researchProduct

Qualitative variations in delay discounting: A brief review and future directions.

2022

The discounting paradigm has been challenged by an increasing number of studies presenting qualitative variations in the individual discount function. Particularly, the subjective value of a loss does not necessarily systematically decrease with delay to the outcome. Qualitative variation refers to variations in shape rather than steepness of the discount function, such as positive discounting, zero discounting, unsystematic discounting, and negative discounting. Data from three previous studies were analysed in terms of qualitative variations observed in delay discounting patterns. Attention was also given to methods used and to the relationship between the results from the various levels …

AdultBehavioral NeuroscienceAdolescentDelay DiscountingRewardVDP::Samfunnsvitenskap: 200::Psykologi: 260HumansAnimal Science and ZoologyGeneral MedicineBehavioural processes
researchProduct